Nanotherapeutics, has been awarded a $20 Million 4-year contract from the National Institute of Allergy and Infectious Diseases (NIAID) to develop an inhaled version of the injectable drug, gentamicin.

Nanotherapeutics, has been awarded a $20 Million 4-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA) to develop an inhaled version of the injectable drug, gentamicin, a broad-spectrum antibiotic that is used as a first-line therapy for pneumonic plague and tularemia, Category A bioterrorism agents. Both diseases are highly infectious and could pose a serious danger if used as an aerosolized biological weapon.

Nanotherapeutics Inc., an emerging specialty pharmaceutical company with expertise in the early stage development of pharmaceuticals, is a privately held corporation located in Florida.

Using its novel particle formulation, the company has developed NanoGENT, an inhaled dry-powder formulation of gentamicin, to provide early treatment for exposure to biological warfare agents, as well as TB and other respiratory infections.

James D. Talton, Ph.D., President and C.E.O. of Nanotherapeutics and co-founder of the company said, that the continued support from the NIAID and BARDA of Nanotherapeutics proprietary drug delivery systems is a terrific endorsement of the company’s  technologies and manufacturing capabilities.